Skip to content

Home Administration of Recombinant Human Erythropoietin in Peritoneal Dialysis Patients: Effectiveness and Safety - A Retrospective Study

Home Administration of Recombinant Human Erythropoietin in Peritoneal Dialysis Patients: Effectiveness and Safety - A Retrospective Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500101868
Enrollment
Unknown
Registered
2025-04-30
Start date
2025-05-13
Completion date
Unknown
Last updated
2025-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic renal failure

Interventions

Observation group:None

Sponsors

Fifth Affiliated Hospital, Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age>=18 years; 2. Gender: male or female; 3. Patients diagnosed with end-stage renal disease according to the guidelines for diagnosis and treatment of chronic kidney disease; 4. From January 1, 2018 to December 31, 2022, he was admitted to the Fifth Affiliated Hospital of Sun Yat-sen University; 5. Received erythropoietin medication for more than 1 month; 6. Peritoneal dialysis catheterization and regular peritoneal dialysis for more than 1 month.

Exclusion criteria

Exclusion criteria: 1. History of tumor in the past; 2. Combined with hemodialysis; 3. Resistant hypertension and/or anemia not caused by renal disease; 4. The clinical data that need to be collected is incomplete.

Design outcomes

Primary

MeasureTime frame
Hemoglobin reaches the standard rate;

Secondary

MeasureTime frame
Hemoglobin reaches the standard rate;

Countries

China

Contacts

Public ContactYang Xiaoying

The Fifth Affiliated Hospital,Sun Yat-sen University

287474050@qq.com+86 13632387610

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026